A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

Valerio only has cash to last three months, according to the DNA decoy specialist. The news comes less than six months after ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Mesenchymal-epithelial transition factor (MET) plays a relevant role in growth, survival, migration and tissue repair. Alterations in MET have been found in non-small-cell lung cancer and head and ...